WO2013158782A3 - Methods and compositions for treating cardiac arrhythmias - Google Patents

Methods and compositions for treating cardiac arrhythmias Download PDF

Info

Publication number
WO2013158782A3
WO2013158782A3 PCT/US2013/037008 US2013037008W WO2013158782A3 WO 2013158782 A3 WO2013158782 A3 WO 2013158782A3 US 2013037008 W US2013037008 W US 2013037008W WO 2013158782 A3 WO2013158782 A3 WO 2013158782A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
cardiac arrhythmias
treating cardiac
subjects
Prior art date
Application number
PCT/US2013/037008
Other languages
French (fr)
Other versions
WO2013158782A2 (en
Inventor
Hua Cai
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Publication of WO2013158782A2 publication Critical patent/WO2013158782A2/en
Publication of WO2013158782A3 publication Critical patent/WO2013158782A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y106/00—Oxidoreductases acting on NADH or NADPH (1.6)
    • C12Y106/03—Oxidoreductases acting on NADH or NADPH (1.6) with oxygen as acceptor (1.6.3)

Abstract

Disclosed herein are methods for treating arrhythmias in subjects which comprise inhibiting or reducing the expression and/or activity of NADPH oxidase 4 (NOX4) in the subjects. Also disclosed are compositions for treating arrhythmias which comprise one or more NOX4 inhibitors.
PCT/US2013/037008 2012-04-18 2013-04-17 Methods and compositions for treating cardiac arrhythmias WO2013158782A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261625763P 2012-04-18 2012-04-18
US61/625,763 2012-04-18

Publications (2)

Publication Number Publication Date
WO2013158782A2 WO2013158782A2 (en) 2013-10-24
WO2013158782A3 true WO2013158782A3 (en) 2014-03-06

Family

ID=49384226

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/037008 WO2013158782A2 (en) 2012-04-18 2013-04-17 Methods and compositions for treating cardiac arrhythmias

Country Status (1)

Country Link
WO (1) WO2013158782A2 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050215624A1 (en) * 2001-12-21 2005-09-29 Kennedy Thomas P Regulation of nad(p)h oxidase growth and transcription in melanoma cells
KR20060087324A (en) * 2005-01-29 2006-08-02 한국생명공학연구원 Method for screening anti-apoptotic agents on nox4 protein of neuronal cells
US20070037883A1 (en) * 2003-02-28 2007-02-15 Dusting Gregory J Therapeutic compositions
US20090203653A1 (en) * 2004-10-04 2009-08-13 Nitromed, Inc. Compositions and Methods Using Apocynin Compounds and Nitric Oxide Donors
US20100316622A1 (en) * 2007-11-02 2010-12-16 University Of Miami Diagnosis and treatment of cardiac disorders
WO2011150299A2 (en) * 2010-05-28 2011-12-01 The Regents Of The University Of California Treatment of myocardial infarction and vascular injury with netrin-1

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050215624A1 (en) * 2001-12-21 2005-09-29 Kennedy Thomas P Regulation of nad(p)h oxidase growth and transcription in melanoma cells
US20070037883A1 (en) * 2003-02-28 2007-02-15 Dusting Gregory J Therapeutic compositions
US20090203653A1 (en) * 2004-10-04 2009-08-13 Nitromed, Inc. Compositions and Methods Using Apocynin Compounds and Nitric Oxide Donors
KR20060087324A (en) * 2005-01-29 2006-08-02 한국생명공학연구원 Method for screening anti-apoptotic agents on nox4 protein of neuronal cells
US20100316622A1 (en) * 2007-11-02 2010-12-16 University Of Miami Diagnosis and treatment of cardiac disorders
WO2011150299A2 (en) * 2010-05-28 2011-12-01 The Regents Of The University Of California Treatment of myocardial infarction and vascular injury with netrin-1

Also Published As

Publication number Publication date
WO2013158782A2 (en) 2013-10-24

Similar Documents

Publication Publication Date Title
AU2018236800B2 (en) DNA-PK inhibitors
WO2016118951A3 (en) Heterocyclic itk inhibitors for treating inflammation and cancer
WO2012072713A3 (en) Lysine demethylase inhibitors such as cyclylcyclopropanamine derivatives for use in the treatment of diseases and disorders associated with flaviviridae
MX2017013983A (en) Use of active agents during chemical treatments.
WO2014062720A3 (en) Methods of treating cancer
WO2012129084A3 (en) Glucosylceramide synthase inhibitors
WO2012104007A3 (en) 7-azaindole derivatives
IL232515A0 (en) Nadph oxidase 4 inhibitors and pharmaceutical compositions containing the same
EP3207940A4 (en) Methods and compositions of neuregulins for preventing, treating or delaying preserved ejection fraction cardiac failure
IN2015DN03069A (en)
WO2013178965A3 (en) Active ingredients activating mitophagy in skin cells and use of same for improving skin condition
WO2010138180A3 (en) Compositions and methods for cardiac tissue repair
WO2010088450A3 (en) Arylamide derivatives useful in the treatment of diseases associated with serca activity
WO2012158672A3 (en) Compounds for use in treatment of mucositis
WO2016022536A3 (en) Inhibitors of myh7b and uses thereof
WO2013006335A3 (en) Methods and compositions useful for treating fitzpatrick type iv, v or vi skin
WO2012076109A3 (en) 2-pyrones
WO2011077163A3 (en) Use
WO2014047653A3 (en) Methods and compositions for extending shelf life of plant products
MX2016015256A (en) Topical lightening composition and methods of use thereof.
WO2012024399A3 (en) Compositions comprising paulownin and/or paulownia extracts and uses thereof
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
WO2013037943A8 (en) Compositions and methods for treating cancer using pi3k beta inhibitor and mapk pathway inhibitor, including mek and raf inhibitors
EP2898891A3 (en) Terminalia chebula and Terminalia bellerica extracts for inhibition of xanthine oxidase
WO2013155465A8 (en) Substituted xanthine derivatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13777996

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13777996

Country of ref document: EP

Kind code of ref document: A2